Search - tctmd.com

Displaying 61 - 80 of 86

Sort: Relevancy | Date

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

L.A. McKeown

January 31, 2019

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

Todd Neale

October 02, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Daily News

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Michael O'Riordan

March 06, 2018

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

Advertisement

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content